Innovative Therapies | Transforming Lives

Investors

Formula For Our Success

Kineta’s mission is to develop novel immuno-therapies that transform patients’ lives. We have refined a process of discovering novel first in class therapies and efficiently advancing them through preclinical development to clinical proof of concept.

All of Kineta’s drug programs are designed to reach valuable inflection points within three to five years, at which point they are made available for license to the larger biopharmaceutical companies. The intellectual property associated with each program is held in a special purpose vehicle protecting investor value, simplifying transactions and maintaining the stability of our parent company. We believe our business model provides tremendous opportunity for the advancement of our drug programs and for strong and early returns to our investors.

Kineta is a privately held corporation that seeks aligned stakeholders who share our vision of improving human health through the development of breakthrough immune-therapies. We encourage interested parties to learn more about Kineta.

For additional information contact our Corporate Development team by sending us a message or by calling 206-378-0400